查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840670

混合成像市场按技术类型、销售管道、应用和最终用户划分 - 全球预测 2025-2032

Hybrid Imaging Market by Technology Type, Sales Channel, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，混合成像市场规模将达到 137.2 亿美元，年复合成长率为 6.88%。

主要市场统计数据
基准年 2024 80.5亿美元
预计年份：2025年 86亿美元
预测年份：2032年 137.2亿美元
复合年增长率 (%) 6.88%

权威的混合成像环境介绍重点阐述了临床驱动因素、技术融合以及医疗保健相关人员的策略重点。

混合影像技术融合了多种技术，契合了不断变化的临床需求和医疗体系发展趋势。近年来，临床医生和技术开发人员致力于整合解剖成像和分子影像技术，以提高诊断特异性和治疗监测效果，并专注于以患者为中心的工作流程和精准医疗。本应用综述概述了关键驱动因素、相关人员的期望以及决策者在评估混合成像技术发展现状时应优先考虑的策略问题。

推动技术应用的因素包括：对复杂适应症诊断信心的提升、影像处理实验室运作效率的提高，以及为获得可量化结果以支持医保报销而进行的必要性评估。同时，检测器设计、影像融合和放射性药物研发的技术创新也催生了新的临床应用情境。因此，医疗机构正从一次性投资的角度，着眼于长期临床项目，重新评估其资本购买策略。

临床医生和管理人员必须权衡资本投入与潜在收益，例如提高诊断效率、减少后续处理以及改善患者管理。因此，他们必须考虑整合临床路径、供应商合作、培训计划等策略，以确保混合影像资产在整体医疗保健领域创造可持续的价值。

技术整合、监管调整和供应链调整如何重新定义混合成像技术对医疗服务提供者和製造商的价值提案

在技​​术融合、监管环境演变和医疗服务模式变革的驱动下，混合成像领域正经历着一场变革。近年来，结合功能和结构影像以提供更丰富诊断资讯的混合成像技术日益成熟，影像处理和人工智慧软体的进步也开始提升诊断的可靠性和工作流程效率。与这些技术发展同步，法律规范和支付方政策也根据混合检测中涌现的证据进行调整，鼓励製造商和临床研究人员设计能够展现有意义临床终点的检测方法。

供应链重组和组件筹资策略正在重塑采购和製造决策，促进模组化设计，并加强系统整合商和放射性药物供应商之间的合作。临床实践也在不断发展，分子特征如今已成为治疗方案指南因素，尤其是在肿瘤学和神经病学领域。这些转变并非渐进式的，而是系统性的，它们重新定义了价值提案，从纯粹以硬体为中心转向包含仪器、示踪剂、分析和服务模式的整合式临床解决方案。

评估2025年关税调整对混合成像价值链的采购、服务连续性和总拥有成本的累积影响

影响跨境贸易和零件关税的政策变化，物流的製造商、经销商和医疗保健系统带来了新的考虑。 2025年关税调整的累积影响正在改变核心子系统、外围组件和放射性药物物流的成本结构，迫使相关人员重新评估筹资策略和供应商合约条款。为此，许多医疗保健机构正在探索近岸外包、供应商多元化和长期采购协议等方式，以降低未来贸易政策波动带来的风险。

临床医生和医院财务团队间接受到设备交付速度减慢和更换零件交货前置作业时间延长的影响；分销商和服务供应商必须重新评估保固和服务水准协议以适应不断变化的成本基础；製造商正在重新评估其全球生产布局，以在不损害监管合规性或品管的情况下保护净利率。

重要的是，关税驱动的环境加速了关于整体拥有成本的讨论，强调维护、培训和临床应用是维持价值的关键槓桿。对于专注于长期专案的相关人员而言，短期措施带来的成本压力凸显了合约弹性、协作的供应关係和情境规划对于维持医疗服务和技术部署连续性的重要性。

深入的细分洞察揭示了技术类型、销售管道、临床应用和最终用户画像如何决定混合成像技术的采用和价值实现。

对市场区隔的深入理解有助于明确临床需求、采购管道和技术偏好之间的交集，从而塑造商业化和部署策略。在评估技术类型时，临床医师和管理者会区分PET-CT、PET-MRI和SPECT-CT，每种技术在敏感度、软组织对比和操作空间方面都各具优势。销售管道也至关重要。选择直销协议或经销商关係会影响合约的灵活性、售后支援和地理覆盖范围，进而影响服务内容和培训计画。

以应用为导向的细分揭示了诊断优先顺序如何驱动成像方式的选择和方案的发展。心臟病学应用，包括心肌灌注和活力检测，需要稳定的定量性能和简化的工作流程来支持高通量心臟计画。感染疾病影像分为感染部位影像和发炎影像，需要灵活的示踪剂选择和快速的影像时间，以指导急诊治疗决策。神经病学应用，例如癫痫和神经退化评估，受益于高解析度分子定位和标准化的解读框架。肿瘤学实践涵盖骨髓恶性肿瘤和固态肿瘤，高度依赖准确的分期和疗效评估来优化治疗顺序。

诊断中心通常优先考虑吞吐量和发表网络，医院强调整合式诊疗路径和多学科协作，而研发则强调方案的灵活性和示踪剂的开发。了解这些维度之间的相互作用，有助于制定商业策略，从而根据每个细分市场的独特需求，量身定制产品特性、服务模式和临床支援。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和细微的市场接受模式将决定差异化的市场进入和成长策略。

区域动态影响技术采纳曲线、报销格局和投资重点，为在美洲、欧洲、中东和非洲以及亚太地区营运的相关人员创造了不同的机会和挑战。在美洲，支付方模式和大型综合医疗系统正在推动对能够显着改善医疗服务流程的高通量解决方案的需求，而区域卓越中心和研究网络则正在加速早期临床应用和通讯协定标准化。资金的取得和整合的采购结构正在简化采购流程，同时更加重视可验证的成果。

由于法规环境和报销机制的差异，欧洲、中东和非洲的医疗技术应用模式呈现出多元化的特征。有些国家采用集中式的国家体系，而有些国家则采用较细分的市场，这种差异影响供应商进入市场和服务交付的方式。相较之下，亚太地区的特点是产能快速扩张、对先进影像处理基础设施的投资不断增加以及国内製造能力的提升，这些因素都会影响价格和供应弹性。在一些市场，人口结构变化和慢性病负担的加重正在推动对精准诊断的需求，而监管审批流程则影响临床整合的步伐。

认识到这些区域差异有助于制定量身定制的打入市场策略、本地证据产生以及反映报销惯例和临床网路成熟度的服务模式。

关键的企业级策略结合了临床伙伴关係、卓越服务和生态系统整合，以确保在混合成像领域获得可持续的竞争优势。

混合成像领域的竞争格局不仅取决于系统效能，还取决于临床伙伴关係、售后支援和生态系统整合。主要企业正透过投资合作研究计画、多中心检验研究和培训计划，降低临床应用门槛，并与关键意见领袖建立长期合作关係。与放射性药物开发商和软体供应商的策略联盟日益普遍，从而能够提供涵盖成像硬体和示踪剂流程的捆绑式解决方案。

卓越的服务也是一项差异化优势，能够提供可预测的维护、快速的零件供应和强大的远距离诊断服务的公司，可以提高设备的运转率和客户满意度。商业模式也从独立的资本销售转向以结果为导向的管理式服务协议转变，使供应商的激励机制与临床应用和病患疗效保持一致。此外，检测器技术、影像重建演算法和示踪剂化学的奖励有助于提升竞争地位，而灵活的部署模式和资金筹措方案则有助于应对不同医疗环境中的预算限制。

能够平衡技术创新、务实服务提供和临床医生参与的市场参与企业，将更有利于赢得长期合约、加入临床网络并影响护理通讯协定。

为供应商和医疗服务提供者提供切实可行的建议，以优化产品设计、供应链弹性、商业化模式和临床参与，从而实现混合成像的成功。

行业领导者应采取多管齐下的方法，使产品开发、商业化和临床应用与不断变化的医疗保健系统优先事项保持一致。首先，应优先考虑模组化系统结构和可互通的软体平台，以便于升级并与电子健康记录和肿瘤资讯系统整合。这将降低客户续订成本，并透过利用现有的数位化工作流程来加速临床应用。其次，与其仅仅关注技术性能指标，不如投资于透过合作测试和真实世界研究来产生临床证据，以证明其对诊断信心、患者管理和诊疗路径的影响。

第三，我们将透过供应商网路多元化、建立区域服务中心以及探索近岸製造方案来增强供应链韧性，从而降低关税和物流风险。第四，我们将发展灵活的商业模式，包括管理服务协议、绩效基本契约和培训套餐，以支援向医院、诊断中心和研发机构的大规模部署。第五，我们将与放射性药物开发公司和人工智慧分析提供者建立策略伙伴关係，以开发解决示踪剂供应、定量成像和决策支援的整合解决方案。

最后，透过参与以临床医生为中心的教育和变革管理计划，支持通讯协定标准化、跨部门协作以及将混合成像见解有效整合到治疗决策中，这些综合行动将使组织能够将技术能力转化为可持续的临床和商业性价值。

采用稳健的混合方法研究途径，结合一手和二手研究以及严格的三角验证，以确保获得基于证据的混合影像学研究结果。

本研究整合了第一手资料和二手资料，并对临床和政策发展进行了结构化回顾，以确保研究检验的平衡。第一手资料包括对临床医生、放射科管理人员、采购负责人和技术专家的深度访谈，从而获得关于临床工作流程、采购标准和服务期望的第一手观点。二手资料包括同行评审的临床研究、监管指南和公开的政策分析，这些资料描述了技术采纳和报销的动态。

透过严格的检验流程，将定量和定性资料进行三角验证，该流程包括将访谈见解与已记录的临床方案和供应商服务内容进行交叉比对。利用已记录的临床用例和通讯协定标准化工作，对技术类型和应用领域进行了比较分析。调查方法的局限性包括依赖已发表的证据以及相关人员是否愿意讨论商业性细节。为了弥补这些不足，分析着重于总结和匿名化的见解，并在证据有限的情况下采用保守的解释。

在整个研究过程中，我们始终遵守伦理考量和资料管治通讯协定，并由多学科专家审查研究结果，以确保其临床和操作有效性。

简明扼要的结论重点阐述了将混合成像创新转化为可衡量的临床和系统级价值所需的策略机会和营运要务。

混合影像代表诊断医学的策略曲折点，它将技术创新与临床工作流程和医疗保健系统目标连结起来。影像方式的融合、分析工具的日益成熟以及放射性药物组合的不断发展，为提高诊断特异性、实现治疗方案个体化以及增强临床决策能力创造了机会。同时，政策和供应链的变化凸显了製定具有韧性的商业策略和灵活的部署模式的必要性，以适应成本结构和法规环境的变化。

价值链上的各相关人员迫切需要透过协作式证据产生、有针对性的临床项目以及支持可持续利用的服务模式，将技术能力转化为可衡量的临床价值。透过将产品开发与临床医生的需求相结合，并建立持久的营运支持，各机构可以确保其混合成像资产在患者管理和系统效率方面带来显着的改进。要充分发挥混合成像在现代医疗保健中的潜力，需要对证据、基础设施和伙伴关係进行协同投资。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过将人工智慧驱动的重建演算法整合到PET/MRI中来提高诊断准确性
  • 可携式混合成像设备的进步使得照护现场肿瘤评估成为可能。
  • PET/CT系统采用数位PET检测器来降低辐射剂量并提高影像品质。
  • 全身PET扫描仪的出现，为研究提供了全面的代谢和功能性影像方法。
  • 扩展频谱混合影像技术，结合PET、SPECT、CT和MRI，用于个人化治疗计画。
  • 透过开发与PET结合的造影MRI序列，实现同步解剖和代谢成像。
  • 实施云端基础的影像分析平台，用于混合影像资料共用和远端协作

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 混合成像市场（依技术类型划分）

  • PET-CT
  • PET-MRI
  • SPECT-CT

9. 混合成像市场（依销售管道划分）

  • 直销
  • 经销商

第十章 混合成像市场（依应用划分）

  • 心臟病学
    • 心肌灌注
    • 生存能力
  • 感染疾病
    • 感染区域的成像
    • 发炎成像
  • 神经病学
    • 癫痫
    • 神经退化
  • 肿瘤学
    • 造血系统恶性肿瘤
    • 固态肿瘤

第十一章 混合成像市场（依最终用户划分）

  • 诊断中心
  • 医院
  • 研究所

第十二章 混合影像市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 混合影像市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国混合影像市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Siemens Healthineers AG
    • GE HealthCare Technologies Inc.
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • Fujifilm Holdings Corporation
    • Hitachi, Ltd.
    • Shimadzu Corporation
    • United Imaging Healthcare Co., Ltd.
    • Neusoft Medical Systems Co., Ltd.
    • Spectrum Dynamics Medical Ltd.
Product Code: MRR-0360AB17DFF6

The Hybrid Imaging Market is projected to grow by USD 13.72 billion at a CAGR of 6.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.05 billion
Estimated Year [2025] USD 8.60 billion
Forecast Year [2032] USD 13.72 billion
CAGR (%) 6.88%

An authoritative introduction to the hybrid imaging environment emphasizing clinical drivers, technology convergence, and strategic priorities for healthcare stakeholders

Hybrid imaging is at the intersection of converging technologies, shifting clinical priorities, and evolving health system imperatives. Over recent years clinicians and technology developers have increasingly integrated anatomical and molecular modalities to improve diagnostic specificity and therapeutic monitoring, driving a focus on patient-centric workflows and precision medicine. This introduction outlines the core drivers, stakeholder expectations, and the strategic questions that decision-makers should prioritize when evaluating the hybrid imaging landscape.

Adoption patterns are influenced by the need for higher diagnostic confidence in complex indications, greater operational efficiency across imaging suites, and the pursuit of quantifiable outcomes that support reimbursement. Simultaneously, technological innovations in detector design, image fusion, and radiopharmaceutical development are enabling novel clinical use cases. As a result, providers are assessing capital acquisition strategies in the context of long-term clinical programs rather than single-use investments.

Clinicians and administrators must balance capital intensity with potential gains in diagnostic throughput, reduced downstream procedures, and improved patient management. Consequently, strategy conversations should integrate clinical pathways, vendor partnerships, and training programs to ensure that hybrid imaging assets deliver sustained value across the care continuum.

How technological convergence, regulatory recalibration, and supply chain realignment are jointly redefining value propositions in hybrid imaging for care providers and manufacturers

The hybrid imaging landscape is experiencing transformative shifts driven by technological convergence, regulatory evolution, and changing care delivery models. Recent years have seen the maturation of hybrid modalities that combine functional and structural imaging to deliver richer diagnostic context, while software advances in image processing and AI have begun to enhance diagnostic confidence and workflow efficiency. Parallel to these technical developments, regulatory frameworks and payer policies are adapting to evidence generated from hybrid studies, prompting manufacturers and clinical investigators to design trials that demonstrate meaningful clinical endpoints.

Supply chain realignment and component sourcing strategies are reshaping procurement and manufacturing decisions, encouraging modular designs and closer collaboration between system integrators and radiopharmaceutical suppliers. Clinical practice is also evolving; multidisciplinary teams are increasingly relying on hybrid imaging to inform personalized treatment plans, particularly in oncology and neurology, where molecular signatures guide therapeutic choices. Taken together, these shifts are not incremental but systemic: they redefine value propositions from purely hardware-centric to integrated clinical solutions encompassing devices, tracers, analytics, and service models.

Assessing the cumulative implications of 2025 tariff adjustments on sourcing, service continuity, and total cost of ownership across hybrid imaging value chains

Policy changes affecting cross-border trade and component tariffs have introduced new considerations for manufacturers, distributors, and health systems that rely on global supply chains. The cumulative impact of tariff adjustments in 2025 has altered cost structures for core subsystems, peripheral components, and radiopharmaceutical logistics, prompting stakeholders to reassess sourcing strategies and contractual terms with suppliers. In response, many organizations have explored nearshoring, diversified vendor bases, and longer-term procurement agreements to mitigate exposure to future trade policy volatility.

Clinicians and hospital finance teams are experiencing indirect effects through slower delivery timelines for capital equipment and increased lead times for replacement parts, which can influence equipment uptime and scheduling. Distributors and service providers have had to revise warranty terms and service-level agreements to accommodate changed cost bases, while manufacturers are reconsidering global production footprints to protect margins without compromising regulatory compliance and quality control.

Importantly, the tariff-driven environment has accelerated discussions about total cost of ownership, emphasizing maintenance, training, and clinical utilization as critical levers to preserve value. For stakeholders focused on long-term programs, the immediate policy-driven cost pressures have underscored the importance of contractual flexibility, collaborative supply relationships, and scenario planning to maintain continuity of care delivery and technology deployment.

Deep segmentation insights revealing how technology type, sales channels, clinical applications, and end-user profiles jointly determine hybrid imaging adoption and value realization

A nuanced understanding of segmentation clarifies where clinical demand, procurement pathways, and technology preferences intersect, shaping commercialization and deployment strategies. When evaluating technology types, clinicians and administrators differentiate offerings across PET-CT, PET-MRI, and SPECT-CT, each delivering distinct advantages in sensitivity, soft-tissue contrast, and operational footprint; these differences influence capital allocation, clinical protocols, and tracer utilization. Sales channels also matter: choices between direct sales engagements and distributor relationships affect contract flexibility, aftermarket support, and regional reach, with implications for service coverage and training programs.

Application-focused segmentation reveals how diagnostic priorities drive modality selection and protocol development. Cardiology applications, including myocardial perfusion and viability studies, demand consistent quantitative performance and streamlined workflows to support high-throughput cardiac programs. Infectious disease imaging, broken down into infection site imaging and inflammation imaging, requires flexible tracer options and rapid imaging timelines to inform acute care decisions. Neurology applications such as epilepsy and neurodegenerative evaluations benefit from high-resolution molecular mapping and standardized interpretation frameworks. Oncology practices, spanning hematologic malignancies and solid tumors, rely heavily on precise staging and response assessment to optimize therapeutic sequencing.

End-user profiles determine procurement cycles and utilization models, with diagnostic centers often prioritizing throughput and referral networks, hospitals emphasizing integrated care pathways and multidisciplinary access, and research institutes focusing on protocol flexibility and tracer development. Understanding how these dimensions interact enables tailored commercial strategies that align product features, service models, and clinical support with the distinct needs of each segment.

Regional dynamics and nuanced adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and growth strategies

Regional dynamics shape adoption curves, reimbursement landscapes, and investment priorities, creating differentiated opportunities and constraints for stakeholders operating across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, payer models and large integrated health systems drive demand for high-throughput solutions that demonstrate clear care pathway improvements, while regional centers of excellence and research networks accelerate early clinical adoption and protocol standardization. Access to capital and consolidated purchasing structures can streamline procurement but also increase emphasis on demonstrable outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory environments and reimbursement structures create a mosaic of adoption patterns; centralized national systems in some countries contrast with more fragmented markets in others, affecting how vendors approach market entry and service delivery. Regional health priorities, such as oncology networks and neurology centers, guide investment in hybrid capabilities and radiopharmaceutical access. By contrast, the Asia-Pacific region is characterized by rapid capacity expansion, increasing investments in advanced imaging infrastructure, and growing domestic manufacturing capabilities that influence pricing and supply resilience. Demographic trends and rising chronic disease burdens in several markets expedite demand for precision diagnostics, while varying regulatory timelines shape the pace of clinical integration.

Recognizing these regional distinctions supports tailored go-to-market strategies, localized evidence generation, and service models that reflect reimbursement realities and the maturity of clinical networks.

Critical company-level strategies that combine clinical partnerships, service excellence, and ecosystem integration to secure durable competitive advantage in hybrid imaging

Competitive landscapes in hybrid imaging are defined not only by system performance but also by clinical partnerships, aftermarket support, and ecosystem integration. Leading organizations are investing in collaborative research programs, multi-center validation studies, and training initiatives that lower barriers to clinical adoption and create durable relationships with key opinion leaders. Strategic alliances with radiopharmaceutical developers and software providers are increasingly common, enabling bundled solutions that address both imaging hardware and tracer pipelines.

Service excellence is another differentiator; companies that provide predictable maintenance, rapid parts availability, and robust remote diagnostics enhance equipment uptime and customer satisfaction. Commercial models are also evolving from standalone capital sales toward outcome-oriented service contracts and managed service agreements that align vendor incentives with clinical utilization and patient outcomes. Additionally, intellectual property in detector technology, image reconstruction algorithms, and tracer chemistry contributes to competitive positioning, while flexible deployment models and financing options help address budgetary constraints in diverse healthcare settings.

Market participants that balance technological innovation with pragmatic service delivery and clinician engagement are better positioned to capture long-term contracts, participate in clinical networks, and influence care protocols.

Actionable recommendations for vendors and providers to optimize product design, supply resilience, commercialization models, and clinical engagement for hybrid imaging success

Industry leaders should adopt a multi-pronged approach that aligns product development, commercialization, and clinical engagement with evolving health system priorities. First, prioritize modular system architectures and interoperable software platforms to facilitate upgrades and integration with electronic health records and oncology information systems. This reduces refresh costs for customers and accelerates clinical adoption by leveraging existing digital workflows. Second, invest in clinical evidence generation through collaborative trials and real-world studies that demonstrate impact on diagnostic confidence, patient management, and care pathways rather than focusing solely on technical performance metrics.

Third, strengthen supply resilience by diversifying supplier networks, establishing regional service hubs, and exploring nearshore manufacturing options to mitigate tariff and logistics risks. Fourth, develop flexible commercial models including managed service agreements, outcome-based contracts, and training bundles that support scalable deployments across hospitals, diagnostic centers, and research institutes. Fifth, build strategic partnerships with radiopharmaceutical developers and AI analytics providers to offer integrated solutions that address tracer availability, quantitative imaging, and decision support.

Finally, commit to clinician-focused education and change management programs that support protocol standardization, cross-disciplinary collaboration, and the effective translation of hybrid imaging insights into treatment decisions. These combined actions will help organizations convert technological capabilities into sustainable clinical and commercial value.

A robust mixed-methods research approach combining primary stakeholder interviews, secondary clinical literature, and rigorous triangulation to ensure evidence-based hybrid imaging insights

This research synthesizes primary interviews, secondary literature, and a structured review of clinical and policy developments to ensure balanced and validated findings. Primary research includes in-depth interviews with clinicians, radiology administrators, procurement leaders, and technical specialists who provide firsthand perspectives on clinical workflows, purchasing criteria, and service expectations. Secondary inputs encompass peer-reviewed clinical studies, regulatory guidance, and publicly available policy analyses that contextualize technology adoption and reimbursement dynamics.

Quantitative and qualitative data were triangulated through a rigorous validation process that included cross-referencing interview insights with documented clinical protocols and supplier service offerings. Comparative analysis of technology types and application areas was performed using documented clinical use cases and protocol standardization efforts. Limitations of the methodology include reliance on available published evidence and stakeholder willingness to discuss commercial specifics; to mitigate these constraints, the analysis emphasizes aggregated and anonymized insights and applies conservative interpretations where evidence was limited.

Ethical considerations and data governance protocols were observed throughout the research process, and findings were reviewed by multidisciplinary experts to ensure clinical plausibility and operational relevance.

A concise conclusion underscoring the strategic opportunity and operational imperatives required to translate hybrid imaging innovations into measurable clinical and system-level value

The synthesis presented here emphasizes that hybrid imaging represents a strategic inflection point for diagnostic medicine, connecting technological innovation with clinical workflows and health system objectives. The convergence of modalities, maturation of analytic tools, and evolving radiopharmaceutical portfolios create opportunities to improve diagnostic specificity, personalize treatment pathways, and enhance clinical decision-making. At the same time, policy and supply chain shifts underscore the need for resilient commercial strategies and flexible deployment models that can adapt to changing cost structures and regulatory environments.

For stakeholders across the value chain, the imperative is to translate technical capabilities into measurable clinical value through collaborative evidence generation, targeted clinical programs, and service models that support sustained utilization. By aligning product development with clinician needs and building durable operational support, organizations can ensure that hybrid imaging assets deliver meaningful improvements in patient management and system efficiencies. The path forward requires coordinated investments in evidence, infrastructure, and partnerships to fully realize the promise of hybrid imaging in modern healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven reconstruction algorithms in PET/MRI for enhanced diagnostic precision
  • 5.2. Advancements in portable hybrid imaging devices enabling point-of-care oncology assessments
  • 5.3. Adoption of digital PET detectors in PET/CT systems to reduce radiation dose and improve image quality
  • 5.4. Emergence of total-body PET scanners for comprehensive metabolic and functional imaging in research
  • 5.5. Expansion of multispectral hybrid imaging combining PET, SPECT, CT and MRI for personalized treatment planning
  • 5.6. Development of contrast-agent free MRI sequences integrated with PET for simultaneous anatomical and metabolic mapping
  • 5.7. Implementation of cloud-based image analysis platforms for hybrid imaging data sharing and remote collaboration

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hybrid Imaging Market, by Technology Type

  • 8.1. Pet-Ct
  • 8.2. Pet-Mri
  • 8.3. Spect-Ct

9. Hybrid Imaging Market, by Sales Channel

  • 9.1. Direct Sales
  • 9.2. Distributors

10. Hybrid Imaging Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Myocardial Perfusion
    • 10.1.2. Viability
  • 10.2. Infectious Diseases
    • 10.2.1. Infection Site Imaging
    • 10.2.2. Inflammation Imaging
  • 10.3. Neurology
    • 10.3.1. Epilepsy
    • 10.3.2. Neurodegenerative
  • 10.4. Oncology
    • 10.4.1. Hematologic Malignancies
    • 10.4.2. Solid Tumors

11. Hybrid Imaging Market, by End User

  • 11.1. Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Hybrid Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hybrid Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hybrid Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Siemens Healthineers AG
    • 15.3.2. GE HealthCare Technologies Inc.
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Canon Medical Systems Corporation
    • 15.3.5. Fujifilm Holdings Corporation
    • 15.3.6. Hitachi, Ltd.
    • 15.3.7. Shimadzu Corporation
    • 15.3.8. United Imaging Healthcare Co., Ltd.
    • 15.3.9. Neusoft Medical Systems Co., Ltd.
    • 15.3.10. Spectrum Dynamics Medical Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYBRID IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HYBRID IMAGING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HYBRID IMAGING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HYBRID IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HYBRID IMAGING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HYBRID IMAGING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HYBRID IMAGING MARKET SIZE, BY PET-MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HYBRID IMAGING MARKET SIZE, BY SPECT-CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HYBRID IMAGING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HYBRID IMAGING MARKET SIZE, BY MYOCARDIAL PERFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HYBRID IMAGING MARKET SIZE, BY VIABILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFECTION SITE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HYBRID IMAGING MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HYBRID IMAGING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HYBRID IMAGING MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HYBRID IMAGING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HYBRID IMAGING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HYBRID IMAGING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HYBRID IMAGING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HYBRID IMAGING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HYBRID IMAGING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL HYBRID IMAGING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. GCC HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. GCC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. GCC HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GCC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GCC HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. GCC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. GCC HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. GCC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 318. GCC HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 319. GCC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. GCC HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. GCC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. GCC HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 323. GCC HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. GCC HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION HYBRID IMAGING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS HYBRID IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS HYBRID IMAGING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS HYBRID IMAGING MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS HYBRID IMAGING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS HYBRID IMAGING MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS HYBRID IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS HYB